Tigatuzumab

Tigatuzumab
Tigatuzumab ?
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target TNFRSF10B (TRAIL-R2)
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 918127-53-4 YesY
ATC code None
Chemical data
Formula C6406H9924N1716O2012S46 
Mol. mass 144.6 kDa
 N(what is this?)  (verify)

Tigatuzumab (CS-1008) is a monoclonal antibody[1] for the treatment of cancer. As of October 2009, a clinical trial for the treatment of pancreatic cancer has been completed,[2] Phase II trials for colorectal cancer[3] and non-small cell lung cancer[4] are running, and a study for ovarian cancer has been approved.[5]

The drug targets member 10b of the tumor necrosis factor receptor superfamily (TNFRSF10B, better known as death receptor 5 or trail receptor 2), a protein overexpressed in many kinds of tumour.[6]

References

  1. ^ WHO Drug Information
  2. ^ NCI: Combination Therapy Targets Pancreatic Cancer Stem Cells
  3. ^ NCI: CS-1008 Used With Irinotecan Versus Irinotecan Alone in Subjects With Metastatic Colorectal Carcinoma Who Failed First-line Treatment With Oxaliplatin
  4. ^ NCI: CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC)
  5. ^ NCI: Combination Chemotherapy With CS-1008 to Treat Ovarian Cancer
  6. ^ NCI: CS-1008
v · d · eMonoclonal antibodies for tumors
Tumor ("-t(u[m])-")
Human ("-tumu-")

Adecatumumab • Belimumab • Cixutumumab • Conatumumab • Daratumumab • Drozitumab • Figitumumab • Ganitumab • Glembatumumab vedotin • Intetumumab • Iratumumab • Lexatumumab • Lucatumumab • Mapatumumab • Narnatumab • Necitumumab • Ofatumumab • Olaratumab • Panitumumab • Pritumumab • Radretumab • Rilotumumab • Robatumumab • Teprotumumab • Votumumab • Zalutumumab

"-melu-" (melanoma): Flanvotumab
Mouse ("-tumo-")

Altumomab pentetate • Anatumomab mafenatox • Arcitumomab • Bectumomab • Blinatumomab • CC49 • Detumomab • Ibritumomab tiuxetan • Minretumomab • Mitumomab • Moxetumomab pasudotox • Naptumomab estafenatox • Nofetumomab merpentan • Pemtumomab† • Pintumomab • Racotumomab • Satumomab pendetide • Taplitumomab paptox • Tenatumomab • Tositumomab • 3F8

"-govo-" (ovarian tumor): Abagovomab • Igovomab • Oregovomab

"-pro-" (prostate tumor): Capromab pendetide

"-colo-" (colonic tumor): Edrecolomab • Nacolomab tafenatox
Chimeric ("-tuxi-")

Amatuximab • Bavituximab • Brentuximab vedotin • Cetuximab • Ensituximab • Girentuximab • Indatuximab ravtansine • Rituximab • Siltuximab • Ublituximab

"-mexi-" (melanoma): Ecromeximab
Humanized ("-tuzu-")
Afutuzumab • Alemtuzumab • Bevacizumab • Bivatuzumab mertansine • Cantuzumab mertansine • Cantuzumab ravtansine • Citatuzumab bogatox • Clivatuzumab tetraxetan • Dacetuzumab • Dalotuzumab • Elotuzumab† • Etaracizumab • Farletuzumab • Ficlatuzumab • Gemtuzumab ozogamicin • Inotuzumab ozogamicin • Labetuzumab • Lintuzumab • Lorvotuzumab mertansine • Matuzumab§ • Milatuzumab • Nimotuzumab • Onartuzumab • Oportuzumab monatox • Pertuzumab • Sibrotuzumab • Tacatuzumab tetraxetan • Tigatuzumab • Trastuzumab • Tucotuzumab celmoleukin • Veltuzumab
Rat/mouse hybrid ("-tumaxo-")


Stub icon This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it. This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.